Hepatocellular Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+Lenvatinib Sponsors: Shanghai Zhongshan Hospital; Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Conditions: Advanced Cancer; Advanced Solid Tumor; Melanoma; Metastasis; Pleural Mesothelioma; Renal Cell Carcinoma; MSI-High; Mismatch Repair Deficiency; Colorectal Cancer; Hepatocellular Carcinoma; Hepatocellular Cancer; Renal Cell Cancer; Kidney Cancer; Skin Cancer; Non Small Cell Lung Cancer; NSCLC; Anaplastic Lymphoma Kinase Genomic Tumor Aberrations; ALK Genomic Tumor Aberrations Interventions: Drug: Alintegimod; Drug: Ipilimumab; Drug: Nivolumab Sponsors: 7 Hills Pharma, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

Econd-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: Cadonilimab+Lenvatinib Sponsors: Hui-Chuan Sun; Sun Yat-sen University; Eastern Hepatobiliary Surgery Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
Conditions: Hepatocellular Carcinoma Interventions: Drug: TKI+Cardunilimab Sponsors: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: camrelizumab Sponsors: Fujian Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
Conditions: Hepatocellular Carcinoma Interventions: Drug: HAIC+STRIDE+Len Sponsors: Sulai Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: Adebrelimab plus Apatinib; Drug: Adebrelimab plus Bevacizumab; Drug: Camrelizumab plus Apatinib Sponsors: Peking University Cancer Hospital& Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials

EchoTip AcuCore Post-Market Clinical Study
Conditions: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis Interventions: Device: EchoTip AcuCore Sponsors: Cook Research Incorporated Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Conditions: Hepatocellular Carcinoma Interventions: Drug: Alectinib (Alecensa), Nivolumab (Opdivo) Sponsors: China Medical University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials

Hepatocellular Carcinoma Liver Organoids
Conditions: Hepatocellular Carcinoma Interventions: Procedure: Liver biopsy Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Conditions: Carcinoma, Hepatocellular Interventions: Drug: HLX53 (1000mg); Drug: HLX53 (2000mg); Drug: HLX10; Drug: HLX04; Other: Placebo Sponsors: Shanghai Henlius Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials

The Study is Being Conducted to to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of Serplulimab Injection (HLX10) and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Conditions: Carcinoma, Hepatocellular Interventions: Drug: HLX53 (1000mg); Drug: HLX53 (2000mg); Drug: HLX10; Drug: HLX04; Other: Placebo Sponsors: Shanghai Henlius Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Conditions: Hepatocellular Carcinoma Interventions: Combination Product: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib Sponsors: Yongyi Zeng Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials

A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer
Conditions: Hepatocellular Carcinoma (HCC) Interventions: Drug: BAY3630942; Drug: BAY3547922 Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials

Early Detection of Liver Cancer by QUS
Conditions: Hepatocellular Carcinoma; Liver Cancer Interventions: Diagnostic Test: Quantitative Ultrasound; Diagnostic Test: B-mode Ultrasound; Diagnostic Test: Magnetic Resonance Imaging; Diagnostic Test: Liver Biopsy Sponsors: Centre hospitalier de l ' Universit é de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l ' Universit é de Montréal; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials